Better Health for All

NeuroOne Medical Technologies Corporation's core business is entirely focused on developing medical devices for neurological disorders. Its products, such as the Evo® sEEG System for epilepsy diagnosis and monitoring, and the OneRF Ablation System for functional neurosurgical procedures and trigeminal nerve ablation, aim to improve surgical outcomes, relieve severe chronic pain, and enhance patient care.

The Evo® sEEG System has passed extensive biocompatibility tests, demonstrating it is non-cytotoxic, non-sensitizing, non-irritating, non-pyrogenic, non-hemolytic, non-mutagenic, non-clastogenic, and negative for systemic toxicity. There is no evidence to suggest that any of the company's products have negative health outcomes.

Fair Pay & Worker Respect

No specific, concrete data points were found in the provided articles to assess NeuroOne Medical Technologies Corporation against the defined KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO-to-median employee pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for the workforce was not available.

While executive compensation details were provided, median employee pay was not disclosed, preventing calculation of the CEO-to-median employee pay ratio. Details about the COO's contract, such as 'at will' employment and benefit participation, did not provide company-wide percentages for insecure contract share or health insurance coverage.

Honest & Fair Business

The company has a Code of Conduct and Ethics in place.

but there is no evidence of specific training frequency or effectiveness metrics, leading to a score of -50 for whistleblower policy. For anti-corruption, the company mentions compliance with the U.S. Foreign Corrupt Practices Act (FCPA) in its risk factors. but lacks details on training frequency or customization for high-risk areas, resulting in a -60. The board's independence is at approximately 75%, with one director participating in a private placement. placing it at -10. The company uses an independent compensation consultant (Grant Thornton) to benchmark and advise on director pay. which represents some third-party verification, but the extent of verification for other ethical claims is not specified, leading to a -50.

No War, No Weapons

NeuroOne Medical Technologies Corporation's Form 10-K Annual Report for the fiscal year ending September 30, 2024, explicitly states that its core business as a medical technology company means defense or arms-related activities are not applicable.

This includes revenue from arms contracts, sales to embargoed regimes, peacebuilding investments, conflict divestment policies, board oversight of defense, export certifications, lobbying, humanitarian procurement, human rights due diligence, Arms Trade Treaty compliance, UN Guiding Principles alignment, dual-use screening, surveillance transparency, ethical red lines, exposure to controversial weapons, war-risk audits, conflict partner reviews, defense divestment, conflict minerals, peace tech investment, conflict zone procurement, and ethical red lines compliance.

Zero Waste & Sustainable Products

NMTC.US achieved a 22% reduction in waste generation in medical device manufacturing in 2023.

The company has implemented ISO 14001:2015 environmental management standards across its production facilities. It has set a target to reduce manufacturing waste by 25% by 2025. In 2023, the company recycled 35% of its electronic waste and 28% of its plastic medical devices. There is no specific data on hazardous waste management, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, or customer waste education.